Tenaya Therapeutics News and Activities

Tenaya Therapeutics is a company listed under the stock ticker TNYA (US).

View the org chart displaying its 26 main executives

Most searched biographies at Tenaya Therapeutics

• Faraz Ali, Chief Executive Officer and Director
• Jeffrey Walsh, Director
• Amy Burroughs, Director

Popular executive movements at Tenaya Therapeutics

• Eric Hyllengren will join the company as Chief Financial Officer on Jul. 13, 2026  (posted on June 30 2026).
• Scott Bertch, Vice President, Clinical Manufacturing and Site Head, has left the company  (posted on June 30 2026).
• David Goeddel, Director, will retire on Jan. 26, 2026  (posted on January 5 2026).

Create your alert
to follow the executive moves at Tenaya Therapeutics.

Tenaya Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Tenaya Therapeutics

• Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference | Tenaya Therapeutics, Inc.
• Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update | Tenaya Therapeutics, Inc.
• View more press releases Close

Social media about Tenaya Therapeutics

• Tenaya Therapeutics on Wikipedia, Google News & Yahoo Finance
• Tenaya Therapeutics on LinkedIn, X (Twitter) & YouTube